MCRB Stock Analysis: Buy, Sell, or Hold?
MCRB - Seres Therapeutics, Inc.
$14.92
-0.36 (-2.36%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When MCRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MCRB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MCRB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MCRB is currently trading at $14.92, which is considered slightly low relative to its 30-day fair value range of $14.89 to $15.72.
Technical Outlook: Technically, MCRB is in a downtrend. The price is currently testing key support at $14.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MCRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+37.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MCRB is in a downtrend. The price is currently testing key support at $14.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MCRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $21.00 (+37.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$14.89 -
$15.72
Company Quality Score
57/100
(HOLD)
Options IV Signal
38th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 38th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 37.4% below Wall St target ($21.00)
Fair Price Analysis
30-Day Fair Range
$14.89 -
$15.72
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$3.02
(20.2%)
Support & Resistance Levels
Support Level
$14.50
Resistance Level
$16.05
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-1.47
Wall Street Target
$21.00
(+37.4%)
Revenue Growth (YoY)
-93.4%
Earnings Growth (YoY)
-91.9%
Profit Margin
1536.8%
Last updated: January 31, 2026 4:01 AM ET
Data refreshes hourly during market hours. Next update: 5:01 AM
Data refreshes hourly during market hours. Next update: 5:01 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MCRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
Advanced MCRB Option Strategies
Professional options setups generated by AI based on today's MCRB price and gamma walls.
